Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

CLL Videos

John Allan, MD, Weill Cornell Medicine
Videos
07/15/2024
John Allan, MD, discusses the treatment regimen he chose for an older patient with high-risk chronic lymphocytic leukemia with deletion 17p who has chronic medical issues such as atrial fibrillation and diabetes.
John Allan, MD, discusses the treatment regimen he chose for an older patient with high-risk chronic lymphocytic leukemia with deletion 17p who has chronic medical issues such as atrial fibrillation and diabetes.
John Allan, MD, discusses the...
07/15/2024
Oncology
John Allan, MD, Weill Cornell Medicine
Conference Coverage
04/10/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
John Allan, MD, Weill Cornell Medicine
Conference Coverage
04/06/2024

Featuring John Allan, MD

Featuring John Allan, MD
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, John Allan, MD, shares expert insight on the impact targeted agents have in the treatment of CLL, focusing particularly on frontline therapy.
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, John Allan, MD, shares expert insight on the impact targeted agents have in the treatment of CLL, focusing particularly on frontline therapy.
At the 2024 Great Debates &...
04/06/2024
Oncology
John Allan, MD
Conference Coverage
03/20/2024

Featuring John Allan, MD

Featuring John Allan, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, John Allan, MD, discusses novel updates in the chronic lymphocytic leukemia treatment landscape, highlighting studies that focused on BTK inhibitor combination treatments.
At the Lymphoma, Leukemia & Myeloma Congress in New York, John Allan, MD, discusses novel updates in the chronic lymphocytic leukemia treatment landscape, highlighting studies that focused on BTK inhibitor combination treatments.
At the Lymphoma, Leukemia &...
03/20/2024
Lymphoma, Leukemia & Myeloma Network
Ira L Zackon, MD
Conference Coverage
12/12/2023

Fetauring Ira L Zackon, MD

Fetauring Ira L Zackon, MD
At the 65th ASH Annual Meeting, Ira L Zackon, MD, presented real-world data from a large community oncology setting on the racial disparities observed in chronic lymphocytic leukemia treatment.
At the 65th ASH Annual Meeting, Ira L Zackon, MD, presented real-world data from a large community oncology setting on the racial disparities observed in chronic lymphocytic leukemia treatment.
At the 65th ASH Annual Meeting,...
12/12/2023
Oncology
Jennifer Brown, MD
Conference Coverage
12/11/2023

Featuring Jennifer Brown, MD

Featuring Jennifer Brown, MD
At the 65th ASH Annual Meeting, Jennifer R Brown, MD, PhD, presented follow-up data which found that zanubrutinib continued to be a more efficacious treatment than ibrutinib for patients with R/R chronic lymphocytic leukemia/small lymphocytic...
At the 65th ASH Annual Meeting, Jennifer R Brown, MD, PhD, presented follow-up data which found that zanubrutinib continued to be a more efficacious treatment than ibrutinib for patients with R/R chronic lymphocytic leukemia/small lymphocytic...
At the 65th ASH Annual Meeting,...
12/11/2023
Oncology
Adrian Wiestner, MD
Conference Coverage
12/11/2023

Featuring Adrian Wiestner, MD

Featuring Adrian Wiestner, MD
At the 65th ASH Annual Meeting, Adrian Wiestner, MD, presented long-term follow-up data on a phase 2 study assessing the efficacy, safety, and depth of response of ibrutinib therapy for patients with CLL.
At the 65th ASH Annual Meeting, Adrian Wiestner, MD, presented long-term follow-up data on a phase 2 study assessing the efficacy, safety, and depth of response of ibrutinib therapy for patients with CLL.
At the 65th ASH Annual Meeting,...
12/11/2023
Oncology
Paolo Ghia, MD, PhD
Conference Coverage
12/10/2023

Featuring Paolo Ghia, MD, PhD

Featuring Paolo Ghia, MD, PhD
At the 65th ASH Annual Meeting, Paolo Ghia, MD, PhD, discusses the importance of assessing minimal residual disease when treating patients with relapsed/refractory chronic lymphocytic leukemia, particularly those with high-risk disease.
At the 65th ASH Annual Meeting, Paolo Ghia, MD, PhD, discusses the importance of assessing minimal residual disease when treating patients with relapsed/refractory chronic lymphocytic leukemia, particularly those with high-risk disease.
At the 65th ASH Annual Meeting,...
12/10/2023
Oncology
Paolo Ghia, MD, PhD
Conference Coverage
12/10/2023

Featuring Paolo Ghia, MD, PhD

Featuring Paolo Ghia, MD, PhD
At the 65th ASH Annual Meeting, Paolo Ghia, MD, PhD, highlights findings from up to 5 years of follow-up of the CAPTIVATE study, which demonstrates the durable efficacy of ibrutinib plus venetoclax as a first-line treatment among patients...
At the 65th ASH Annual Meeting, Paolo Ghia, MD, PhD, highlights findings from up to 5 years of follow-up of the CAPTIVATE study, which demonstrates the durable efficacy of ibrutinib plus venetoclax as a first-line treatment among patients...
At the 65th ASH Annual Meeting,...
12/10/2023
Oncology
Susan M. O'Brien, MD
Videos
08/17/2023

Featuring Susan M. O'Brien, MD

Featuring Susan M. O'Brien, MD ...
Susan M. O'Brien, MD, discusses the possible applications of pirtobrutinib, a noncovalent BTK inhibitor, for the treatment of patients with CLL.
Susan M. O'Brien, MD, discusses the possible applications of pirtobrutinib, a noncovalent BTK inhibitor, for the treatment of patients with CLL.
Susan M. O'Brien, MD, discusses...
08/17/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement